Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06589596 · ClinicalTrials.gov registry record · Phase 1

An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors

A Phase 1 study of Advanced Solid Tumor, sponsored by BeOne Medicines.

Recruiting
Registry status
Phase 1
Development phase
244
Enrollment target
20
Study locations

NCT06589596: Recruiting Phase 1 study of Advanced Solid Tumor, sponsored by BeOne Medicines.

NCT06589596 is a Phase 1 study of Advanced Solid Tumor that is actively recruiting participants, run by BeOne Medicines. The registered enrollment target is 244 participants, above the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (27% higher). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06589596, a Phase 1 study of Advanced Solid Tumor, is actively recruiting participants, sponsored by BeOne Medicines.

RECRUITING
Registry status
Phase 1
Development phase
244 participants
Enrollment target
20
Study locations

Study Summary

This is an open-label, multicenter, first-in-human dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BGB-58067 alone, in combination with BG-89894, and in combination with standard of care therapy in participants with advanced solid tumors and with methylthioadenosine phosphorylase (MTAP) deficiency.

Primary Outcome

Number of participants with AEs and SAEs, including findings from physical examinations, electrocardiograms (ECGs), and laboratory assessments.

Conditions Studied

Advanced Solid Tumor

Interventions

  • DRUG BG-89894
  • DRUG BGB-58067
  • DRUG Standard of Care Therapy

Study Locations (20)

Beijing Municipality

  • Cancer Hospital Chinese Academy of Medical Sciences - Beijing
  • Beijing Cancer Hospital - Beijing
  • Beijing Chest Hospital, Capital Medical University - Beijing

Texas

  • The University of Texas Md Anderson Cancer Center - Houston
  • Next Dallas - Irving

Victoria

  • Monash Health - Clayton
  • Austin Health - Heidelberg

California

  • Usc Norris Comprehensive Cancer Center (Nccc) - Los Angeles

Florida

  • Adventhealth - Celebration

Massachusetts

  • Dana Farber Cancer Institute - Boston

Missouri

  • Washington University School of Medicine - St Louis

New York

  • Nyu Langone Health - New York

Trial Details

FieldValue
Enrollment Target 244 participants
Start Date 2024-10-11
Est. Completion 2029-01
Phase Phase 1
BeOne Medicines

29 total trials

What NCT06589596 shows while recruiting

NCT06589596 is an interventional study that assigns participants to a tested intervention. The registered 244 participants enrollment target is mid-sized for trials with a published cap, above the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (27% higher).

The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 3 interventions - of which BG-89894 is the first listed.

NCT06589596 names 20 study sites across 16 states, led by Beijing Municipality, Texas, Victoria.

Frequently Asked Questions

What is clinical trial NCT06589596 about?

NCT06589596 is a clinical study titled "An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors". This is an open-label, multicenter, first-in-human dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BGB-58067 alone, in combination with BG-89894, and in combination with standard of care therapy ...

What is the current status of trial NCT06589596?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 244 participants. The study started on 2024-10-11. Estimated completion is 2029-01.

What conditions does trial NCT06589596 study?

This clinical trial studies the following conditions: Advanced Solid Tumor.

What interventions are being tested in trial NCT06589596?

The interventions under investigation include: BG-89894 (DRUG), BGB-58067 (DRUG), Standard of Care Therapy (DRUG).

Who is sponsoring clinical trial NCT06589596?

This trial is sponsored by BeOne Medicines, which has 29 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06589596 being conducted?

This trial has 20 study locations across California, Florida, Massachusetts, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06589596's enrollment target sits among peer trials

244 48th of 189 higher than 142 of 189 other Advanced Solid Tumor trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02227251 · 244 participants · Phase 2

    Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

  • NCT04317534 · 244 participants · Phase 2

    Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm

  • NCT04683250 · 244 participants · Phase 1

    Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities

  • NCT04686305 · 244 participants · Phase 1

    Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06589596

Source: ClinicalTrials.gov NCT06589596, the US trial registry maintained by the National Library of Medicine. NCT06589596 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.